Key facts
- This page summarizes Richard P. Bryce's Form 4 filing for enGene Holdings Inc. (ENGN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Dec 2023, 17:55.
Richard P. Bryce - 30 Nov 2023 Form 4 Insider Report for enGene Holdings Inc. (ENGN)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- ENGN
- Reported as of
- 30 Nov 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Dec 2023, 17:55:37 UTC
- Prior SEC filing
- 31 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard P. Bryce
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Richard P. Bryce filed Form 4 for enGene Holdings Inc. (ENGN) on 04 Dec 2023.
Change
- Previous filing in this sequence was filed on 31 Oct 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ENGN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +153,000
- Change %
- Price
- $0.000000
- Shares after
- 153,000
- Date
- 30 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 153,000
- Exercise price
- $7.66
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option vests at 25% on the first anniversary of the grant date, with the remaining portion to vest monthly over the remaining three years.